Direct detection of breast cancer markers in serum has been demonstrated for luminal A type breast cancers, which are estrogen-receptor positive, HER2 negative, and Ki67 low; the protein Ki67 can be used to track cell proliferation and high levels of Ki67 are associated with negative outcomes [94]. This evidence concerns the gene MKI67 and breast carcinoma.